National Academies Press: OpenBook
« Previous: Appendix B: Speaker Biographies
Suggested Citation:"Appendix C: Resources." Institute of Medicine. 2009. Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12219.
×
Page 128
Suggested Citation:"Appendix C: Resources." Institute of Medicine. 2009. Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12219.
×
Page 129
Suggested Citation:"Appendix C: Resources." Institute of Medicine. 2009. Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12219.
×
Page 130
Suggested Citation:"Appendix C: Resources." Institute of Medicine. 2009. Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12219.
×
Page 131
Suggested Citation:"Appendix C: Resources." Institute of Medicine. 2009. Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12219.
×
Page 132

Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Appendix C Resources A number of resources mentioned throughout the workshop are avail- able on the internet. The following list is provided as a starting point for those interested in the development of drugs for rare and neglected diseases. The Forum does not endorse any particular programs, publications, or websites. Organizations and Initiatives National Organization for Rare Disorders (NORD) http://www.rarediseases.org/ FasterCures, The Center for Accelerating Medical Solutions http://www.fastercures.org/ See white paper: Entrepreneurs for Cures: The Critical Need for Innovative Approaches to Disease Research, May 30, 2008. http://www.fastercures.org/objects/pdfs/white_papers/FastercuresWP_ Innovation_052808.pdf Drugs for Neglected Diseases initiative (DNDi) http://www.dndi.org/ U.S. Food and Drug Administration (FDA) FDA http://www.fda.gov/ 128

APPENDIX C 129 FDA Office of Orphan Products Development http://www.fda.gov/orphan/ Funding FDA Orphan Products Grants Program http://www.fda.gov/orphan/grants/index.htm FDA Cooperative Research and Development Agreements http://www.fda.gov/oc/ofacs/partnership/techtran/default.htm Guidance for Industry Fast Track Drug Development Programs—Designation, Development, and Application Review http://www.fda.gov/cder/guidance/5645fnl.pdf Formal Meetings with Sponsors and Applicants for PDUFA Products http://www.fda.gov/cder/guidance/2125fnl.pdf E 10 Choice of Control Group and Related Issues in Clinical Trials http://www.fda.gov/cder/guidance/4155fnl.pdf Special Protocol Assessment http://www.fda.gov/cder/guidance/3764fnl.PDF Code of Federal Regulations (CFR) and Federal Food, Drug, and Cosmetic Act (FFDCA) Title 21: Food and Drugs (21 CFR) Chapter I: Food and Drug Administration, Department of Health and Human Services (Parts 1–1299) http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm 21 CFR § 316 Orphan Drugs http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch. cfm?CFRPart=316 Priority Review and Priority Review Voucher, FFDCA, Section 524 http://www.fda.gov/opacom/laws/fdcact/fdcact5b.htm

130 BREAKTHROUGH BUSINESS MODELS National Institutes of Health (NIH) NIH Office of Rare Diseases http://rarediseases.info.nih.gov/ Funding NIH National Center for Research Resources (NCRR), Clinical and Translational Science Awards (CTSA) http://www.ncrr.nih.gov/clinical_research_resources/clinical_and_ translational_science_awards/ Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs http://grants1.nih.gov/grants/funding/sbirsttr_programs.htm Guidelines and Standardized Agreements Uniform Biological Material Transfer Agreement (UBMTA) http://www.autm.net/aboutTT/aboutTT_umbta.cfm Principles and Guidelines for Recipients of NIH Research Grants and Contract on Obtaining and Disseminating Biomedical Research Resources http://www.ott.nih.gov/policy/reasearch_toolarchive.html Examples of Data and Materials Sharing Repositories NIH AIDS Research and Reference Reagent Repository https://www.aidsreagent.org/Index.cfm MR4: Malaria Research and Reference Reagent Resources Program http://www.mr4.org/ BEI Resources: Biodefense and Emerging Infectious Diseases Research Resources Repository http://www.beiresources.org/ ScienceCommons Biological Materials Transfer Project http://sciencecommons.org/projects/licensing/ LONI Image Data Archive https://ida.loni.ucla.edu/login.jsp?project=ADNI%2f

APPENDIX C 131 Genetic Alliance BioBank http://biobank.org Intellectual property Management Socially Responsible Licensing at Berkeley—Humanitarian Use Clauses in Contracts http://ipira.berkeley.edu/—then “Socially Responsible IP Management” link Clinical Trials Small Clinical Trials: Issues and Challenges (IOM report, full text free online) http://www.iom.edu/CMS/3740/5483.aspx ClinicalTrials.gov Registry http://clinicaltrials.gov/ Declaration of Helsinki, the World Medical Association http://www.wma.net/e/policy/b3.htm

Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies: Workshop Summary Get This Book
×
Buy Paperback | $49.00 Buy Ebook | $39.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

The process for developing new drug and biologic products is extraordinarily expensive and time-consuming. Although large pharmaceutical companies may be able to afford the cost of development because they can expect a large return on investment, organizations developing drugs to treat rare and neglected diseases are unable to rely on such returns.

On June 23, 2008, the Institute of Medicine's Forum on Drug Discovery, Development, and Translation held a public workshop, "Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies," which sought to explore new and innovative strategies for developing drugs for rare and neglected diseases.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  6. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  7. ×

    View our suggested citation for this chapter.

    « Back Next »
  8. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!